NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading APLS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 42% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementModerate volatility — typically moves about 1% a day.
View RiskAPLS's growth depends on strong sector trends and recent financial performance. Revenue has been strong, and the last quarter showed a significant beat. It trades at a premium compared to peers, which suggests high expectations. If APLS cuts guidance on the next call, it could face a significant drop. Peer multiples imply a price about 12% above where it trades; this read is provisional.
Trailing returns as of 2026-05-14. APLS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 20 analysts currently covering APLS (as of May 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Advances: Completion of Acquisition by Biogen
Acquisition completion aligns with strategic growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-05-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
